Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys

Gene Therapy

Volumn 11, Issue 3, 2004, Pages 241-252

  Haegel kronenberger, H ^a   Haanstra, K ^b   Ziller Remy, C ^a   Ortiz Buijsse, A P ^c   Vermeiren, J ^d   Stoeckel, F ^a   van Gool, S W ^d   Ceuppens, J L ^d   Mehtali, M ^a,e   de Boer, M ^c   Jonker, M ^c   Boon, Luis ^c,f  

^a TRANSGENE S A   (France)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c Pangenetics   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Deltagen Europe   (France)

^f BIOCEROS   (Netherlands)

Author keywords

Adenovirus; Costimulation blockade; Rhesus monkey; Transient immunosuppresion

Indexed keywords

ADENOVIRUS VECTOR; B7 2 PROTEIN; B7-2 PROTEIN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; CD86 ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD86; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADENOVIRUS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BIOSYNTHESIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INHIBITION KINETICS; LIVER; LIVER PARENCHYMA; LYMPHOCYTIC INFILTRATION; MACACA; MALE; METHODOLOGY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; TRANSGENE; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD86; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; LIVER; MACACA MULATTA; MALE; MEMBRANE GLYCOPROTEINS; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MACACA; MACACA MULATTA; PRIMATES;

EID: 10744229480     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302152     Document Type: Article

References (35)

1. Wilson JM. Molecular medicine: adenoviruses as gene delivery vehicles. Mol Med 1996; 334: 1185-1187.
2. Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
3. Christ M et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997; 57: 19-25.
4. Sullivan DE et al. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997; 8: 1195-1206.
5. Schnell MA et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vector. Mol Ther 2001; 3: 708-722.
6. Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 1999; 94: 3968-3975.
7. Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 1999; 10: 2515-2526.
8. Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
9. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Virol 1995; 25: 3467-3473.
10. Yang Y, Lin Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
11. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
12. Michou A-I et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
13. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
14. Shean MK et al. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates. Hum Gene Ther 2000; 11: 1047-1055.
15. Kafri T et al. Cellular immune response to adenoviral vector-infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
16. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258.
17. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135.
18. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
19. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune response to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370-6377.
20. Scaria A et al. Antibody to CD40L inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airways. Gene Therapy 1997; 4: 611-617.
21. Chirmule N et al. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol 2000; 74: 3345-3352.
22. Kay MA et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686-4691.
23. Ziller C, Stoeckel F, Boon L, Haegel-Kronenberger H. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Gene Therapy 2002; 9: 537-546.
24. Boon L et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 2001; 167: 2942-2949.
25. Laman JD et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 2002; 32: 2218-2228.
26. Boon L et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 2002; 174: 53-65.
27. Haanstra KG et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637-643.
28. Schreiber RD, Farrar MA. The biology and biochemistry of interferon-gamma and its receptor. Gastroenterol Jpn 1993; 28 (Suppl): 4-88.
29. Zoltick PW et al. Biology of E1-deleted adenovirus vector in nonhuman primate muscle. J Virol 2001; 75: 5222-5229.
30. Chirmule N et al. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a non-depleting CD4 antibody. J Immunol 1999; 163: 448-455.
31. Van Gool SW et al. Blocking CD40-CD154 and CD80/CD86-CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production. Eur J Immunol 1999; 29: 2367-2375.
32. Koenen HJPM, Joosten I. Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood 2000; 95: 3153-3161.
33. Chartier C et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in E. coli. J Virol 1996; 70: 4805-4810.
34. Lusky M et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72: 2022-2032.
35. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovectors for gene therapy. J Virol 1996; 70: 7498-7509.